Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical immunology"
DOI: 10.1016/j.clim.2017.06.007
Abstract: Eculizumab is a monoclonal anti-C5 antibody used in the treatment of atypical hemolytic uremic syndrome (aHUS). We monitored complement inhibition in 16 eculizumab-treated patients suffering from HUS or transplant rejection (not aHUS patients). Blood samples… read more here.
Keywords: alternative complement; complement pathway; pathway hemolytic; blockade ... See more keywords